Great information concerning EAPH listed below....
Easton Pharmaceuticals and BMV Medica Announce Placing Initial Order for Both of Its Patented Women's Health Diagnostic Products for the Mexico Market From Manufacturer, CommonSense Inc.
TORONTO, ON--(Marketwired - Feb 1, 2016) - Easton Pharmaceuticals Inc. (OTC PINK: EAPH) In keeping with Easton's Focus on Women's Health, and together with its partner BMV Medica, the company announces it has placed an initial order for both the vaginal discharge diagnsostic test (VS-Sense) and the amniotic fluid leak test (AmnioSense) from manufacturer CommonSense of Israel, with delivery expected in late March, to coincide with a planned April launch.
This first-order of the CommonSense products is for the Mexican launch with the total number of units ordered at 230,000, - 90,000 units of the VS-Sense and 140,000 units of the AmnioSense, enough product for launch and three-six months of sales. Easton/BMV anticipate to file the regulatory dossier for VS-Sense early this week, and expect approval prior to the expected delivery date of this first order in late March. The AmnioSense diagnostic test as well as the Gynofit bacterial vaginosis treatment are already approved in Mexico through third-party consultants. BMV is in the process of having the Marketing Approvals (registrations) transferred to BMV Medica, so all three products can be launched at the same time. Easton/BMV will be placing an initial order for Gynofit with the Swiss manufacturer over the next few weeks.
Easton/BMV anticipate the bulk of its sales initially from the Obstetrician/Gynecologist community in Mexico and have already received its first orders following the introduction of these new products this past November at the OB/GYN conference in Acapulco, attended by approximately 4,000 of the 7,000 gynecologists in Mexico. The VS-Sense products recently starting selling in most western European countries through German based, Multi National Pharmaceutical company, Bayer Pharmaceuticals Inc. where all indications are that sales have exceeded expectations. Easton / BMV and other industry professionals anticipate the products to sell very well in Mexico and most latin American markets where Easton / BMV possess exclusive distribution and licensing rights.
The Amnio-Sense diagnostic product currently approved for sale in Mexico is currently owned exclusively by BMV. Easton is in high level discussions with BMV to include AmnioSense for Mexico with an agreement currently in place. AmnioSense is already part of the agreement for the rest of Latin America.
Product Listing
Amnio-Sense Amniotic Fluid Diagnostic Test Approval
Easton Pharmaceuticals and its partner BMV have the rights to the approved amniotic fluid leak test for rest of Latin America, and is in the process of final packaging for the Latin American market under the EvaPro brand. Sales could begin immediately once commercial alliances have been established in the region. These exclusive licensing rights were jointly purchased by Easton and BMV Medica from Israel-based Common Sense Inc. on a 50/50 profit sharing agreement which encompasses the countries in Central and South America except Brazil. The AL-Sense Amniotic Fluid Diagnostic Leak Test to be called AmnioSense is a patented women's diagnostic product that is currently being sold in the United Kingdom, and has European Approval. It serves a huge market, and the birth rate in Latin America is three times the birth rate in North America and most of Europe. The target market for BMV/Easton has a population exceeding 200 million people. Sales in Latin America for pharmaceutical and diagnostic products are expected to grow at a rate five times that of North America and Europe as a result of a much higher birthrate in the region and other factors as well.
